Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome

Inclusion Criteria Concurrent Medication: Allowed: * Corticosteroids for up to 21 days at doses no greater than 20 mg/day prednisone (higher doses may be given for shorter durations, if clinically indicated). * Zidovudine, oral contraceptives, methadone, narcotics, acyclovir, acetaminophen, sulfonamides, trimethoprim/sulfamethoxazole, pentamidine for Pneumocystis carinii pneumonia (PCP) or PCP prophylaxis, topical antifungals, pyrimethamine, ganciclovir. * Didanosine (ddI), dideoxycytidine (ddC), foscarnet, or other investigational drugs considered to be essential for patient management. Concurrent Treatment: Allowed: * Transfusion. Patients must have the following: * HIV infection. * Histoplasmosis. * Appropriate consent must be obtained from a parent or legal guardian for patients less than 18 years of age. Allowed: * Hematologic and/or renal laboratory abnormalities. * Concurrent malignancies. * Concurrent infection with Mycobacteria. * Patients with severe manifestations of histoplasmosis who are thought to be at risk of dying within one week should receive up to 250 mg amphotericin B for up to seven days prior to enrollment and then be re-evaluated. Patients who are still severely ill and do not meet eligibility criteria may not enter the study. Specific criteria defining life-threatening histoplasmosis include: * Systolic blood pressure \< 90 mm Hg without other cause; arterial pO2 \< 60 torr without other cause; and SGOT \> 10 x upper limit of normal or bil…